• Evaluation Criteria
• FAQs

Word Count: All abstract categories have a 300 count word limit.

Original Research: Abstract Deadline: March 27, 2023, 11:59 p.m. (PST)

Abstracts must summarize quantitative or qualitative findings from completed research. Basic, clinical, translational, dissemination/implementation, or educational research are examples of acceptable research. Topics should appeal to a clinical pharmacy audience and may include research in drug metabolism, education/pedagogy, health services, medication safety, patient/population outcomes, pharmacokinetics, pharmacodynamics, pharmacoeconomics, pharmacoepidemiology, pharmacogenomics, pharmacology, or pharmacotherapy. Abstracts reporting in vitro or animal research are welcome.

• Abstracts must be structured with the section headers of: Introduction, research question or hypothesis, study design, methods, results, and conclusions.
• Abstracts will be evaluated based on merits of the research question/hypothesis, study design, originality, methods, data analysis, results, and conclusions.
• Descriptions of planned research efforts or preliminary data will not be accepted.
• Original research findings presented elsewhere, but important to clinical pharmacy, are encouraged as “Encore” submissions (see Encore Presentation details below).
• A previously presented abstract may form the basis for a new abstract to be submitted for consideration in the Original Research category if the previous abstract:
• 1. was a descriptive report of planned research only,
  2. described preliminary results only and complete results are now available,
  3. was presented at a student, resident, or fellow conference focused on gaining presentation experience and/or formative feedback,
  4. was presented at an ACCP Chapter or PRN event, or
  5. conclusions have been added/modified based on a new hypothesis and data analysis of the original results database.

• Evaluation Criteria
• FAQs

Advances in International Clinical Pharmacy Practice, Education, or Training: Abstract Deadline: March 27, 2023, 11:59 p.m. (PST)

Abstracts must describe the development, delivery, justification, or documentation of clinical pharmacy practice, education, or training outside of the United States. Abstracts may be descriptive and need not contain an evaluative component.

Abstracts must be structured with the section headers of:< Service or program, justification/documentation, adaptability, and significance

Abstracts will be evaluated based on the originality of the service or program to the specific setting, adequacy of justification/documentation, adaptability to other settings, and significance to international clinical pharmacy advancement.

• Evaluation Criteria
• FAQs

Systematic Reviews/Meta-Analyses: Abstract Deadline: March 27, 2023, 11:59 p.m. (PST)

Abstracts must describe a systematic review adhering to the guidelines and definitions established by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA for Abstracts statement) and include the 12-items published in the PRISMA for Abstracts checklist (http://www.prisma-statement.org/Extensions/Abstracts).

Abstracts must be structured with the PRISMA for Abstracts format: Background, methods, results, discussion, and other

Abstracts will be evaluated based on merits of the 12 PRISMA for Abstracts checklist items: Title, objectives, eligibility criteria, information sources, risk of bias, included studies, synthesis of results, description of the effect, strengths and limitations of evidence, interpretation, funding, and registration.

Scoping Reviews: Abstract Deadline: March 27, 2023, 11:59 p.m. (PST)

Abstracts must describe a scoping review adhering to the guidelines and definitions established by Preferred Reporting Items for Scoping Reviews (PRISMA for Scoping Reviews) and include the 10-items described in the ACCP-adapted PRISMA for Abstracts checklist (ACCP-adapted PRISMA for Scoping Review Abstracts checklist).

Abstracts must be structured with the PRISMA for Abstracts format: Background, methods, results, discussion, and other

Abstracts will be evaluated based on merits of the 10 ACCP-adapted PRISMA for Scoping Review Abstracts checklist items: Title, objectives, eligibility criteria, information sources, charting methods, included studies, synthesis of results, limitations, conclusions, and funding. Note: the Evaluation Criteria link above pertains only to Systematic Reviews.

Abstracts presented elsewhere, but important to clinical pharmacy, are encouraged as "Encore" submissions (see Encore Presentation details below).

• Evaluation Criteria
• FAQs

Case Reports: Abstract Deadline: March 27, 2023, 11:59 p.m. (PST)

Abstracts of case reports must update and expand therapeutic insights and possibilities, or generate research hypotheses. While narrative in nature, these abstracts must stress the 'evidence' for the authors' conclusions by describing the process followed to understand the findings and possible mechanisms involved in the patient's case, how the patient was evaluated and treated, and a specific description of the outcome.

Abstracts must be structured with the section headers: Introduction, case, discussion, and conclusion.

Case report abstracts will be evaluated based on the abstract criteria recommended by the CARE Guidelines (CAse REport Group, http://www.care-statement.org/resources/checklist): uniqueness of report, clinical findings presented, outcomes documented, and “take-away” lessons.

Abstracts of case reports presented elsewhere, but important to clinical pharmacy, are encouraged as "Encore" submissions (see Encore Presentation details below).

• Evaluation Criteria
• FAQs

Clinical Pharmacy Forum: Abstract Deadline: March 27, 2023, 11:59 p.m. (PST)

Abstracts must describe the development, delivery, justification, or documentation of new or innovative clinical pharmacy services. Abstracts that address components of the ACCP Standards of Practice for Clinical Pharmacists (see www.accp.com/standards) and/or describe efforts to develop, advance, or position clinical pharmacists to optimize patient care are encouraged. Abstracts may be descriptive and need not contain an evaluative component.

Abstracts must be structured with the section headers of: Service or program, justification/documentation, adaptability, and significance.

Abstracts will be evaluated based on originality of the service or program, adequacy of justification/documentation, adaptability to other settings, and significance to clinical pharmacy.

• Evaluation Criteria
• FAQs

Word Count: All abstract categories have a 300 count word limit.

Original Research: Abstract Deadline: March 27, 2023, 11:59 p.m. (PST)

Abstracts must summarize quantitative or qualitative findings from completed research. Basic, clinical, translational, dissemination/implementation, or educational research are examples of acceptable research. Topics should appeal to a clinical pharmacy audience and may include research in drug metabolism, education/pedagogy, health services, medication safety, patient/population outcomes, pharmacokinetics, pharmacodynamics, pharmacoeconomics, pharmacoepidemiology, pharmacogenomics, pharmacology, or pharmacotherapy. Abstracts reporting in vitro or animal research are welcome.

• Abstracts must be structured with the section headers of: Introduction, research question or hypothesis, study design, methods, results, and conclusions.
• Abstracts will be evaluated based on merits of the research question/hypothesis, study design, originality, methods, data analysis, results, and conclusions.
• Descriptions of planned research efforts or preliminary data will not be accepted.
• Original research findings presented elsewhere, but important to clinical pharmacy, are encouraged as “Encore” submissions (see Encore Presentation details below).
• A previously presented abstract may form the basis for a new abstract to be submitted for consideration in the Original Research category if the previous abstract:
• 1. was a descriptive report of planned research only,
  2. described preliminary results only and complete results are now available,
  3. was presented at a student, resident, or fellow conference focused on gaining presentation experience and/or formative feedback,
  4. was presented at an ACCP Chapter or PRN event, or
  5. conclusions have been added/modified based on a new hypothesis and data analysis of the original results database.

** A copy of the original abstract and the full citation of where/when the research was presented must accompany submission. ACCP reserves the right to determine the extent of difference necessary to substantiate a new Original Research abstract submission.

• Submit Now
• FAQs

Residents and Fellows Research-in-Progress: Abstract Deadline: April 10, 2023, 11:59 p.m. (PST)

Submission guidelines are those of an Original Research abstract except that the research effort is ongoing at the time of abstract submission.

• The presenting author must be in a post-graduate training program (PGY-1 or PGY-2 residency, Ph.D./Masters graduate degree program, or fellowship training program).
• Abstracts submitted in the Research-in-Progress category are not eligible for the Resident and Fellow Best Poster competition. *Note: to be eligible for the Best Poster competition, the research must meet the criteria for and be submitted under the Original Research category, indicating that it was conducted by a resident or fellow.
• In-Progress abstracts will not be published in JACCP 

• Submit Now
• FAQs

Student Research-in-Progress: Abstract Deadline: April 10, 2023, 11:59 p.m. (PST)

Submission guidelines are those of an Original Research abstract except that the research effort is ongoing at the time of abstract submission.

• The presenting author must be a first professional degree (Pharm.D. or B.S. Pharm.) student.
• Abstracts submitted in the Research-in-Progress category are not eligible for the Student Best Poster competition. *Note: to be eligible for the Best Poster competitions, the research must meet the criteria for and be submitted under the Original Research category, indicating that it was conducted by a student.
• In-Progress abstracts will be not published in JACCP.

• FAQs

Word Count: All abstract categories (with the exception of Encore submissions) have a 300 count word limit.

Encore: Abstract Deadline: March 27, 2023, 11:59 p.m. (PST)

Encore Presentation:  Encore presentation are accepted in the Original Research, Systematic Reviews/Meta-Analyses, or Case Reports categories only. Abstracts submitted for the Encore Presentation category must not be modified from the previously presented/published version. This includes the title, authors, and abstract body. The presenting author may change, but the author must be an author on the original abstract.

• Abstracts submitted for Encore Presentations must not be modified from the previously presented/published version. This includes the title, authors, and abstract body. The presenting author may change, but the author must be an author on the original abstract.
• The same abstract may not be presented at more than one national ACCP event.
• Only the abstract title, authors, and original citation will be published in JACCP.

• Submit Now
• FAQs

Word Count: All abstract categories have a 300 count word limit.

MeRIT Preliminary Results: Abstract Deadline: April 10, 2023, 11:59 p.m. (PST)

• Submit Now
• FAQs

Word Count: All abstract categories have a 300 count word limit.

MeRIT Complete Research: Abstract Deadline: April 10, 2023, 11:59 p.m. (PST)